Journal of Clinical Investigation

Oncology & Cancer

Predicting outcome for high-dose IL-2 therapy in cancer patients

One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going ...

Diseases, Conditions, Syndromes

Identifying targets of autoantibodies

Patients with the autoimmune disease systemic lupus erythematosus (SLE) produce autoantibodies that target can cause damage to multiple organ systems. The host factors that are targeted by autoantibodies produced by SLE patients ...

Medical research

Balancing T cell populations

Depending on the signals received, naïve T cells are able to differentiate into mature T cell populations, which play different roles in the immune system. For example, regulatory T cells (Tregs) are important for tamping ...

Medical research

Insights into type 2B von Willebrand disease

In response to blood vessel damage, von Willebrand factor (vWF) binds to the exposed extra cellular matrix, recruits platelets to the site of injury, and activates platelets, which promotes thrombis formation. Patients with ...

Oncology & Cancer

Tipping the balance between senescence and proliferation

An arrest in cell proliferation, also referred to as cellular senescence, occurs as a natural result of aging and in response to cellular stress. Senescent cells accumulate with age and are associated with many aging phenotypes, ...

page 11 from 23